Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan DEBIRI: Multi-Institutional RegistryReport as inadecuate




Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan DEBIRI: Multi-Institutional Registry - Download this document for free, or read online. Document in PDF available to download.

Journal of OncologyVolume 2009 2009, Article ID 539795, 6 pages

Clinical Study

Division of Surgical Oncology, University of Louisville School of Medicine, 315 East Broadway-Rm 311, Louisville, KY 40292, USA

Interventional Radiology Radiology, Baptist Health, 9601 Lile Dr, Radiology Consultants, Little Rock, AR 72212, USA

Interventional Radiology Radiology, Huntsville Hospital, 1963 Memorial Pkwy SW, Radiology of Huntsville, Huntsville, AL 35801, USA

Radiology & Imaging Consultants, PC, Institute for Minimally Invasive Therapy, Colorado Springs, CO 80910, USA

Norton Healthcare Radiology, 200 E Gray St, Louisville, KY 40202, USA

Received 6 May 2009; Revised 10 August 2009; Accepted 30 September 2009

Academic Editor: Douglas S. Tyler

Copyright © 2009 Robert C. G. Martin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The purpose of this study was to evaluate the patient tolerance and efficacy of delivering locoregional chemotherapy to metastatic colorectal MC hepatic metastases via hepatic trans-arterial approach using irinotecan loaded drug eluting beads. This open-label, multi-center, single arm study included 30 MC patients, who had failed first line therapy. Of the 57 total embolization sessions, 12 21% of sessions were associated with adverse reactions during or after the treatment. After a median followup of 9 months, response rates by modified RECIST were 75% at 3 months and 66% at 6 months. Hepatic trans-arterial therapy using Irinotecan loaded DC was safe and effective in the treatment of MCC as demonstrated by a minimal complication rate and acceptable tumor response.





Author: Robert C. G. Martin, Jonathan Joshi, Ken Robbins, Dana Tomalty, Ryan O'Hara, and Cliff Tatum

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents